SNOA

$2.40

Post-MarketAs of Mar 17, 8:00 PM UTC

Sonoma Pharmaceuticals, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.40
Potential Upside
5%
Whystock Fair Value$2.52
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-81.18%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.21

Recent News

Zacks
Aug 19, 2025

Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Aug 14, 2025

Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut

Walmart, Amazon Deal Sends Sonoma Pharmaceuticals Stock Into Frenzy

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Associated Press Finance
Aug 14, 2025

BC-Most Active Stocks

Nu Holdings Ltd. 57,985,829 12.32

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Jul 14, 2025

Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Yahoo Finance
Jul 10, 2025

The early winner in the 'Dexit' war for corporate relocations: Nevada

Companies from Andreessen Horowitz to Pershing Square are choosing Nevada as they follow Elon Musk's exit from Delaware.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.